Total votes: 8

Major facilities in Australia, Germany, Switzerland and the US, CSL has over 10,000 employees working in 27 countries.

Net sales of $1,129 million for the six months ended June 30, 2009

Plasma Products: Human plasma is used to produce a wide range of life-saving medicines. CSL's various businesses support all aspects of the process from the collection and testing of donated plasma through to the production of a range of plasma-derived products.

The key businesses involved with plasma products include: CSL Behring is a global provider of plasma-derived & recombinant products. We operate one of the world's largest plasma collection networks through CSL Plasma CSL Bioplasma is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan. 

CSL also manufacture and market in vitro diagnostic products through Immunohaematology Vaccines & Pharmaceuticals. The company manufactures and provide influenza vaccine globally.

In Australia and New Zealand, CSL Biotherapies also markets a comprehensive range of vaccines and antivenoms as well as a range of pharmaceutical products supplied by other manufacturers.

Research & Development: Activities at CSL are focused on new product development, life-cycle management and safety of an extensive product portfolio. CSL invests in the development of protein-based medicines for treating serious human diseases. Medicines can be made from plasma, traditional biological sources or using recombinant biotechnology.

Competition:

 - Talecris